title: The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.
authors: C
authors: C
authors: Albers
authors: H
authors: H
authors: Leischner
authors: M
authors: M
authors: Verbeek
authors: C
authors: C
authors: Yu
authors: A L
authors: AL
authors: Illert
authors: C
authors: C
authors: Peschel
authors: N
authors: N
authors: von Bubnoff
authors: J
authors: J
authors: Duyster
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D052160:Benzothiazoles / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics*; D008875:Middle Aged; D009154:Mutation; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*; D019311:Staurosporine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077210:Sunitinib; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics* / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents; D052160:Benzothiazoles; D007211:Indoles; D010671:Phenylurea Compounds; D011758:Pyrroles; C544967:quizartinib; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3; D019311:Staurosporine; C059539:midostaurin; D000077210:Sunitinib